N. Hiyashi,
M.P. Manns
Springer Netherlands
2004e druk, 2004
9780792387961
Prevention of Progression in Chronic Liver Disease
An Update on SNMC (Stronger Neo-Minophagen C). In honour of Hans Popper's 100th birthday
Specificaties
Gebonden, 130 blz.
|
Engels
Springer Netherlands |
2004e druk, 2004
ISBN13: 9780792387961
Rubricering
Onderdeel van serie
Falk Symposium
Verwachte levertijd ongeveer 9 werkdagen
Samenvatting
In several liver diseases, the underlying cause cannot always be eliminated, i.e. the progression of liver disease cannot be prevented. This is particularly true for non-responders to the treatment of chronic hepatitis C (HCV). It is relevant for more than 40% of patients with HCV genotype 1 and up to 20% of patients with genotype 2 or 3. Several approaches are now underway to prevent or ameliorate mechanisms of disease progression. In Asia, and particularly in Japan, Glycyrrhizine-SNMC has been widely used for this purpose. At present, SNMC is under clinical evaluation in Europe.
Specificaties
ISBN13:9780792387961
Taal:Engels
Bindwijze:gebonden
Aantal pagina's:130
Uitgever:Springer Netherlands
Druk:2004
Serie:Falk Symposium
Inhoudsopgave
<P>List of Principal Authors. Preface. Introduction; <EM>H Suzuki</EM>. 1: Mechanisms of fibrogenesis; <EM>B Stefanovic, J Lindquist, RA Rippe, B Schnabl, R Schwabe, R Bataller, DA Brenner</EM>. 2: Non-invasive markers of liver injury;<EM> V Ratziu, T Poynard.</EM> 3: Complications of cirrhosis: the relevance of hepatocellular carcinoma; <EM>M Colombo, M Iavarone</EM>. 4: Controlling necroinflammation of liver with SNMC (Stronger Neo Minophagen C): therapy on interferon non-responders; <EM>S Lino</EM>. 5: Predictive parameters of non-response to standard hepatitis treatment; <EM>H Wedemeyer</EM>. 6: Concepts for the treatment of non-responders in hepatitis C; <EM>S Zeuzem.</EM> 7: Glycyrrhizin: the molecule and present knowledge of action in various liver diseases; <EM>K Shiraki, H Sato, M Kurokawa, Y Yoshida</EM>. 8: Dendritic cells in immune responses against hepatitis C virus; <EM>N Hayashi, T Kanto, T</EM> <EM>Takehara</EM>. 9: SNMC in the prevention of cirrhosis and hepatocellular carcinoma: Japanese experience; <EM>K Ikeda</EM>. 10: SNMC in interferon non-responders with chronic hepatitis C: European experience in controlled trials; <EM>S Schalm, TGF van Rossum, H Orlent, BE Hansen</EM>. Index</P>
